Three stock recommendations ahead of marijuana legalization

This post was originally published on this site

Courtesy of Globe and Mail

Matt Bottomley, the Alternative Pharmaceuticals research analyst at Canaccord Genuity, recently spoke with The Globe and shared his thoughts on the cannabis market

Leave a Reply

Your email address will not be published.